Impact of sofosbuvir and daclastavir on health-related quality of life in patients co-infected with hepatitis C and human immunodeficiency virus.

Evy YunihastutiFhadilla AmeliaArini Ika HapsariBramantya WicaksanaVeritea NataliAlvina WidhaniAndri Sanityoso SulaimanTeguh Harjono Karjadi

Published in: Health and quality of life outcomes (2021)

HCV/HIV co-infected patients were successfully treated with sofosbuvir and daclatasvir and experienced improvement of HRQoL 12 weeks after treatment completion.

Keyphrases

hepatitis c virus
human immunodeficiency virus
end stage renal disease
antiretroviral therapy
chronic kidney disease
ejection fraction
hiv positive
newly diagnosed
prognostic factors
hiv infected
hiv testing
hepatitis c virus infection
south africa
patient reported outcomes
gestational age